Zheng Quan Ri Bao Wang·2025-11-19 12:45Core Insights - The strategic cooperation seminar held by Guangzhou Pharmaceutical Group and Guangzhou Baiyunshan Pharmaceutical Group focused on the theme "New Journey Without Boundaries, Together Towards the Future" and gathered over 430 guests from various sectors [1][2] - Guangzhou Pharmaceutical Group aims to achieve modernization, digitalization, technological advancement, and internationalization as part of its "14th Five-Year Plan" to accelerate the goal of "recreating a new Guangzhou Pharmaceutical" [1] Group 1 - Guangzhou Pharmaceutical Group's capital operations are robust, with a fund subscription scale of 4.7 billion yuan and actual contributions of 2.4 billion yuan, focusing on innovative drugs and high-end medical devices [1] - The company is advancing its technological innovation with nearly 20 new drugs under research and 26 new product projects added this year [1] - International expansion is entering a new phase, with ongoing efforts to explore markets in Southeast Asia, the Middle East, and South America [1] Group 2 - A key highlight of the seminar was the announcement of the nuclear medicine industry layout and the innovative achievements of Guangzhou Baiyunshan's nuclear health pharmaceutical company [2] - A strategic cooperation agreement was signed between Baiyunshan and GE Healthcare to empower the high-quality development of the nuclear medicine industry through cross-industry collaboration [2] - The launch of the "China Innovative Drug R&D and Industry Development Research Report Project" aims to integrate resources across the industry chain and address challenges in innovative drug development, supporting China's transition from a major pharmaceutical country to a strong pharmaceutical nation [2]